Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects
NCT: NCT06854120 · RECRUITING
Brief Summary
Functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is weak. Prokinetic agents (e.g., metoclopramide, erythromycin) and symptom modulators (e.g., nortriptyline, mirtazapine) are commonly used, but selecting the right medication can be difficult, as it's often based on symptoms rather than the underlying gastric issues. Body Surface Gastric Mapping (BSGM) using the Gastric Alimetry device is a novel, non-invasive tool to assess gastric myoelectrical activity and symptoms. This study aims to perform two BSGM recordings-one before and one after medical therapy-to understand how medications affect gastric function and identify baseline BSGM factors that could predict responses to treatment, potentially guiding tailored therapies based on individual gastric dysfunction.
Frequently Asked Questions
What is Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects?
Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects is a clinical trial registered under NCT06854120. Current status: RECRUITING.
What is the status of NCT06854120?
The current status of NCT06854120 (Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects) is: RECRUITING.
When did Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects start?
Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients: Baseline and Treatment Effects started on 2025-02-26.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.